\. With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood ++ 2\. Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix 3. Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before) 4. Patients with an allergic history of Levamisole Hydrochloride and Anlotinib Hydrochloride Capsules 5. The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic pressure#90 mmHg) 6. Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men 450 ms; women 470 ms) 7. Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF#50% 8. Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs 9. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study 10. Dysfunction of blood coagulation(INR#2.0 or PT 16s APTT > 43s TT > 21sFbg < 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score 2 11. Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present 12. Urine routine showed that urine protein ++ or the urine protein in 24 hours#1.0 g 13. Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study. 14. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives 15. Patients with mental sickness or the history of psychotropic drug abuse 16. Patients with severe infection (unable to control the infection effectively) 17. The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year) 18. The researchers believe that any other factors unsuitable for entering into the study
Yes for \. With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood ++ 2\. Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix 3. Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before) 4. Patients with an allergic history of Levamisole Hydrochloride and Anlotinib Hydrochloride Capsules 5. The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic pressure#90 mmHg) 6. Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men 450 ms; women 470 ms) 7. Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF#50% 8. Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs 9. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study 10. Dysfunction of blood coagulation(INR#2.0 or PT 16s APTT > 43s TT > 21sFbg < 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score 2 11. Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present 12. Urine routine showed that urine protein ++ or the urine protein in 24 hours#1.0 g 13. Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study. 14. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives 15. Patients with mental sickness or the history of psychotropic drug abuse 16. Patients with severe infection (unable to control the infection effectively) 17. The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year) 18. The researchers believe that any other factors unsuitable for entering into the study exclusion criteria 1
No for \. With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood ++ 2\. Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix 3. Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before) 4. Patients with an allergic history of Levamisole Hydrochloride and Anlotinib Hydrochloride Capsules 5. The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic pressure#90 mmHg) 6. Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men 450 ms; women 470 ms) 7. Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF#50% 8. Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs 9. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study 10. Dysfunction of blood coagulation(INR#2.0 or PT 16s APTT > 43s TT > 21sFbg < 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score 2 11. Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present 12. Urine routine showed that urine protein ++ or the urine protein in 24 hours#1.0 g 13. Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study. 14. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives 15. Patients with mental sickness or the history of psychotropic drug abuse 16. Patients with severe infection (unable to control the infection effectively) 17. The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year) 18. The researchers believe that any other factors unsuitable for entering into the study exclusion criteria 1
Not sure for \. With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood ++ 2\. Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix 3. Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before) 4. Patients with an allergic history of Levamisole Hydrochloride and Anlotinib Hydrochloride Capsules 5. The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure#140 mmHg, diastolic pressure#90 mmHg) 6. Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men 450 ms; women 470 ms) 7. Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF#50% 8. Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs 9. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study 10. Dysfunction of blood coagulation(INR#2.0 or PT 16s APTT > 43s TT > 21sFbg < 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score 2 11. Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present 12. Urine routine showed that urine protein ++ or the urine protein in 24 hours#1.0 g 13. Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study. 14. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives 15. Patients with mental sickness or the history of psychotropic drug abuse 16. Patients with severe infection (unable to control the infection effectively) 17. The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year) 18. The researchers believe that any other factors unsuitable for entering into the study exclusion criteria 1